Abstract Purpose: Ewing sarcoma (EWS) is the second most common sarcoma of bone in children and young adults. Patients with disseminated disease at diagnosis or early relapse have a poor prognosis. Our goal was to identify novel predictive biomarkers for these patients, focusing on chemokines, specifically genes involved in the CXCR4-pathway because of their established role in metastasis and tumour growth. Methods: Total RNA isolated from therapy-naïve tumour samples (n = 18; panel I) and cell lines (n = 21) was used to study expression of CXCR4-pathway related genes and CXCR4 splice variants (CXCR4-2: Small and CXCR4-1: Large) by RT-Q-PCR. Expression levels were correlated to overall survival (OS) and event free survival (EFS). Study results were validated in an independent series of 26 tumour samples (panel II) from therapy-naïve tumour samples. Results: CXCL12, CXCR4, CXCR7 and CXCL14 were expressed and high CXCR7 and CXCL14 expression showed a positive correlation with EFS and OS and a negative European Journal of Cancer (2015) 
Introduction
Ewing sarcoma (EWS) is the second most common bone neoplasm in children and young adolescents while soft tissue and organ related involvement is more often observed in adults [1] . Genetically, EWS is characterised by a recurrent translocation of the EWSR1 gene to a member of the family of ETS transcription factors [1, 2] . Rarely, tumours with Ewing sarcoma-like features exist were EWSR1 is fused to a non-ETS family member or between BCOR-CCNB3 or CIC-DUX4 genes [1, [3] [4] [5] .
The introduction of multi-agent chemotherapy in combination with advancements in surgery and radiotherapy has improved the 5-year overall survival (OS) of EWS patients with localised disease from less than 10-70% nowadays, irrespective of the type of classical Ewing sarcoma specific translocation [6, 7] . However, the OS drops to less than 30% when metastases are present at the time of diagnosis which is the case in 15-30% of new presentations-or with tumour relapse [8, 9] . For these high risk patients many markers have been suggested, but at present only classical markers, such as tumour location, are used in clinic [10] . EWS is recognised from the onset of its original description by James Ewing as a highly vascularised tumour and amongst many other pathways, chemokine and the TGF-B pathway might play a role for this excessive vascularisation pattern [11] [12] [13] . Besides angiogenesis, these pathways are involved in migration that might be reflected by the high metastatic propensity of EWS [1, 13, 14] . In several tumour types a positive correlation between increased expression of CXCR4 and metastatic propensity was reported, but contradictory results were reported in EWS [15] [16] [17] .
CXCR4 is a chemokine receptor from the G-protein coupled receptor family binding the CXC chemokines. CXCR4 ligands are chemokine CXCL12, also known as stromal cell-derived factor 1 (SDF1) and CXCL14, also known as BRAK [18, 19] .
For CXCR4 two common splice variants have been described in humans by Gupta et al. containing either two exons CXCR4-2 or one exon by utilising another transcription initiation code inside intron one CXCR4-1 [20] . At the protein level, the first five amino acids at the N-terminus of CXCR4-2 are replaced with nine amino acids in the CXCR4-1 variant. Hence, the N-terminal part of CXCR4 is crucial in CXCL12 binding therefore this change may interfere with CXCR4 activation [20, 21] . The expression levels of these two splice variants have neither been studied in tumour samples nor associated with survival.
To study the role of different chemokines and their receptors in combination with the detection of different CXCR4 isoforms we performed whole transcriptome RNA sequencing and a real-time quantitative-reverse transcriptase PCR (RT-Q-PCR) on EWS cell lines and two panels of therapy-naïve tumour samples (test and a validation set: panel I and panel II). Results of the RT-Q-PCR were correlated to clinical parameters. Survival analysis of panel I showed that high CXCR4-1 over CXCR4-2 ratio and high expression of CXCL14 and CXCR7 positively correlated with EFS and OS. These findings were overall confirmed by a validation set (panel II). Thus, CXCL14, CXCR7 and the ratio between CXCR4-2 and CXCR4-1 could predict EFS and OS in Ewing sarcoma patients, which is probably related to their role in CXCR4 signalling pathway.
Material and methods

Clinical information patient samples
Ewing sarcoma diagnosis was established according to World Health Organisation (WHO) criteria, including immunohistochemistry and EWSR1 translocation detection either by RT-Q-PCR or interphase FISH. 18 cryopreserved therapy-naïve samples from 18 patients containing at least 80% tumour were collected at the Department of Pathology, Leiden University Medical Center (Table 1A; 
RNA isolation
Total RNA was isolated using TRIzol Reagent (Life Technologies, Bleiswijk, The Netherlands) according to manufacturer's instruction. RNA concentration was measured using Nanodrop and quality of the RNA was determined using Bioanalyzer2000 RNA Nano chip (Agilent Technology, Amstelveen, The Netherlands). For whole transcriptome RNA sequencing analysis a RNA Integrity Number (RIN) of 8 was set as threshold. For the RT-Q-PCR analysis the inclusion criteria were at least a RIN of 5 and measurable expression levels.
CXCR4 splice variant specific primer design and detection
CXCR4 splice variant specific primers sets were designed for RT-Q-PCR based expression analysis. CXCR4-2 primers CXCR4-2F 5 0 AGGTAGCAAAGTG ACGCCGA 3 0 and CXCR4-2R 5 0 TAGTCCCCTGAG CCCATTTCC 3 0 were intron spanning by priming exon 1 and exon 2. CXCR4-1 primers were CXCR4-1F 5 0 GACTTTGAAACCCTCAGCGTC 3 0 and CXCR4-1R 5 0 TCCTACAACTCTCCTCCCCAT 3 0 . Products were detected by using 10ul RT-Q-PCR mixture using iQ SYBR Green supermix (Biorad, Hercules, CA, USA).
RT-Q-PCR analysis and Fluidigm
cDNA generation and RT-Q-PCR using Fluidigm biomark system was performed according to the H format instructions of the manufacturer (QIAGEN, Venlo, The Netherlands). Samples were prepared for RT-Q-PCR using a 96 Â 96 dynamic array chip and performed using BioMark HD system (Fluidigm, San, CA, USA). All primers for this array chip were obtained from QIAGEN (Venlo, The Netherlands) including nine control genes: RPL13A, BTF3, YWHAZ, UBE2D2, ATP6V1G1, IPO8, HBS1L, AHSP and TBP. Samples were measured in duplicates and analysed using BioMark software, delivered with the HD system.
Whole transcriptome RNA sequencing
RNA sequencing was performed at BGI genomics (Hong Kong, People's Republic of China) following standard protocol established by BGI genomics. In short, total isolated RNA was enriched for mRNA using Oligo(dT) beads and generated fragments were size selected for amplification. Amplified fragments were quality controlled and sequenced using Illumina HiSeq 2000. Reads were aligned to a reference sequence using SOAPaligner/SOAP2. Gene expression was calculated using Reads Per Kilobase per Million mapped reads (RPKM) method [23] .
Statistical analysis
Survival curves were calculated using the KaplanMeier method and P-values were calculated using the log-rank and Gehan Breslow Wilcoxon test using SPSS 20 (IBM Inc. Amsterdam, The Netherlands) and Prism Graphpad 6 (Graphpad Software Inc. La Jolla, CA, USA). Correlations were calculated with SPSS 20 using Spearman or Pearson correlation. High RNA expression was set as expression above the median. Student t-tests P-value was calculated using Prism Graphpad assuming non-parametric distribution due to limited numbers of samples and were corrected using ManleyWelch correction.
Results
EWS expresses all CXCR4-CXCR7 axis genes and tumour samples have an increased CXCR4-1/CXCR4-2 ratio
RNA expression levels of chemokines and their receptors in cell lines were analysed using both Fluidigm RT-Q-PCR and whole transcriptome analysis. Both methods showed comparable expression levels and that all genes involved in the CXCR4-CXCR7 axis were expressed (Fig. 1) . We performed an expression analysis of a CXCR4-CXCR7 axis chemokine and their receptor gene set, from which expression differences were observed for CXCR7 and CXCL12 between cell lines and tumour samples, using a panel of 18 therapy naïve tumour samples, 21 cell lines and 1 primary culture (Tables 1A and 2 ). The cell line RT-Q-PCR expression levels of the CXCR4-CXCR7 axis genes were compared with expression levels in tumour samples and showed an increased expression of CXCL12 and CXCR7 in tumour samples. Furthermore, within the cell lines and among individual tumour samples a large variation was observed ( Fig. 2A) . Fig. 3 . Overview of CXCR4-CXCR7 axis genes and event free survival (EFS), overall survival (OS) in panel 1 and panel 2. CXCR4-1/-2 ratio and CXCL14 expression were associated with a significant better EFS in both panels, CXCR7 in panel I with OS in panel I. RNA expressions of the CXCR4-CXCR7 axis genes of the therapy-naïve tumour samples of panel I (n = 18) (A-C, G-I) and panel II (n = 25) (D-F, J-L) were correlated using Kaplan-Meier survival analysis. Median was set as threshold between high (straight line, panel I n = 9, panel II n = 13) and low expression (dotted line, panel I n = 9, panel II n = 12). A significant association between high CXCR4-1/CXCR4-2 ratio and improved EFS or OS was observed in both panels. Fig. 4 . Model for CXCR4 signalling in Ewing sarcoma: CXCL12 binds and activates CXCR4-2, which is inhibited by CXCL14 and CXCR7 by inhibiting receptor binding and scavenging of CXCL12. Dimerisation of CXCR4-1 and CXCR4-2 results in CXCR4 activation inhibition due to either change in CXCR4-2 signalling or by higher CXCR4-1 affinity for CXCL14. As available therapeutic options (boxed red) are CXCL14 analogues, CXCL12 neutralisers and CXCR4 inhibitors (see [19, 36, 37] ). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Both splice variants of CXCR4 were expressed in all tumour samples and cell lines except the A673 cell line and no significant difference was observed between the groups (Fig. 2B) . The ratio between splice variants has been shown to be functionally relevant, therefore we further analysed the ratio between expression levels of CXCR4-1 and CXCR4-2 in our samples [24] . The CXCR4-1/CXCR4-2 ratio was uniformly distributed in the cell line panel with two outliers; A673 cell line without CXCR4-1 expression and COH cell line with a high CXCR4-1/CXCR4-2 ratio (Table S1 ). Tumours samples of panel I demonstrated a wide distribution (range 0.06-0.003, SD = 0.015) and an overall significantly higher CXCR4-1/CXCR4-2 ratio when it was compared to cell lines (median of 0.030 versus 0.012, P < 0.001) (Fig. 2C). 3.2. CXCR4-1 over CXCR4-2 ratio, CXCR7 and CXCL14 expression associate with development of metastases and survival
The large observed variation in CXCR4-CXCR7 axis genes and in the CXCR4-1/CXCR4-2 between individual tumour samples prompted us to perform a comparison between patient samples. A survival analysis was performed using the CXCR4-CXCR7 axis gene expressions and the CXCR4-1/CXCR4-2 ratio of the primary therapy-naïve tumour samples. We observed that a high CXCR4-1/CXCR4-2 ratio and high expression of CXCL14 and CXCR7 correlated with an improved event free survival (EFS) (P < 0.03, P < 0.01, P < 0.02) and OS (P < 0.03, P < 0.02, P < 0.01), respectively ( Fig. 3A-C, G-I) . Consistent with the correlations with improved survival were increased CXCL14 (P < 0.02) and CXCR7 (P < 0.02) expression negatively correlated with the development of metastasis. The results were validated with an independent second panel of 25 therapy-naïve tumour samples using the same methods (Table 1B ; panel II). The same pattern of survival associations with improved EFS was observed for increased CXCR4-1/CXCR4-2 ratio (P < 0.05) and expression of CXCL14 (P < 0.04) (Fig. 3D and I) , while the expression of CXCL14 (P < 0.02) and CXCR7 (P < 0.03) showed a negative correlation with the development of metastasis. Expression of CXCR7 was associated with improved EFS but did not reach a significant level (Fig. 3F) . No association to overall survival was observed in panel II (Fig. 3J-K) . Expression levels of CXCR4 or CXCL12 did not show significant correlation with survival in either panel. (Fig. S1A-H) . As control experiment a survival analysis was performed using the classical prognostic parameters tumour volume, metastasis at diagnosis, location and metastasis after diagnosis of both panels [25] . The development of metastasis after diagnosis was strongly associated with poor survival (P < 0.01) consistent with panel I. A pelvic located tumour correlated with a significant poor EFS and OS in panel I, while these were not significant in panel II. Intriguingly, metastasis at diagnosis did not correlate significantly with survival in both panels (Fig. S2 ).
Discussion
In earlier studies a crucial role of the CXCR4/CXCR7 axis in solid tumour development and prognosis has been reported [17, 19, 26] . Recent discoveries regarding the receptor-receptor and novel ligand-receptor interaction between CXCR4, CXCR7, CXCL12 and CXCL14 have been reported. Contradictory results in Ewing sarcoma prompted us to study the role of these chemokines in therapy-naïve patient material and cell lines [15, 16, 18] . In addition, we studied expression levels of the earlier reported CXCR4 isoforms in tumour samples as the expression of these isoforms in particular might partly be responsible for the contradictory results [15, 16, 20] . All chemokines and receptors of the CXCR4-CXCR7 axis were expressed in EWS but a large variation was observed between individual samples, consistent with previous observations [16, 27] . The observed increased expression of CXCR7 and CXCL12 in tumour samples compared to cell lines could be stromal derived since both endothelial and perivascular cells express CXCR7 and CXCL12 and EWS is highly vascularised [28, 29] . In our results, increased expressions of CXCL14, CXCR7 and CXCR4-1/CXCR4-2 ratios were associated with better EFS and OS in panel I. In panel II increased CXCL14 expression and CXCR4-1/CXCR4-2 ratio were associated with better EFS. However, CXCL12 and CXCR4 mRNA expression levels did not correlate significantly with EFS or OS. In both panels there was an inverse correlation of increased expression of CXCL14 and CXCR7 and development of metastases. This can be related to immune cell infiltration [30, 31] . Classical clinical parameters were included to compare with the newly identified parameters. In panel II none of the classical parameters were significant predictors of survival. This cohort has been extensively treated by different rescue protocols after failure of the initial treatment.
Contrary to our results, increased expression of CXCR4 or CXCR7 has been reported to be associated with poor survival in EWS and other tumours [16, 17] . This might be attributed to different methodologies and patient groups used in different studies or might be related to biological effects between different tumour types. For example, the effect of CXCR4 and CXCR7 is dependent on their spatial-temporal distribution. When they are expressed in the same cell, heterodimers can be formed leading to an enhanced CXCR4 downstream signalling [26] . When CXCR7 is expressed alone it can act as scavenging receptor for CXCL12 and subsequently reduces CXCR4 activation by CXCL12 [32] . By flow cytometry and immunohistochemistry a heterogeneous CXCR4
